BAMCO Inc’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

BAMCO Inc’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-42,750	Closed	-$4.59M	–	369
2023 Q1	$4.59M	Buy	42,750 +30,950	+262%	+$3.56M	0.01%	266
2022 Q4	$1.3M	Buy	+11,800	New	+$765K	﹤0.01%	325

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

BAMCO Inc's RXDX Position: Q2 2023 in Review

BAMCO Inc sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 42,750 shares — an estimated $4.59M sold.

BAMCO Inc first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $4.59M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

BAMCO Inc reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
BAMCO Inc sold 42,750 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $4.59M.
BAMCO Inc first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
BAMCO Inc's Prometheus Biosciences, Inc. Common Stock position peaked at $4.59M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on BAMCO Inc's 13F filing for Q2 2023, filed 14 Aug 2023.